BMS 182874是一种内皮素 ETA 受体拮抗剂，能够有效降低大鼠高血压模型中的血压，适用于心血管疾病的研究。

Carperitide, also called as Atrial Natriuretic Peptide (ANP) (1-28), is a 28-amino acid hormone, that is normally produced and secreted by the human heart in response to cardiac injury and mechanical stretch.

Sparsentan是一种双重拮抗剂，能够同时作用于血管紧张素 II (angiotensin II) 和内皮素 A (endothelin A) 受体，具有在高血压和心血管疾病治疗中的应用潜力。

IRL-2500 is a potent endothelin receptor antagonist with IC50 values of 1.3 and 94 nM for ETB and ETA receptors respectively.

Zibotentan is an orally administered, potent and specific ETA-receptor (endothelin A receptor) antagonist (IC50 = 21 nM).

Ro 46-8443 is the first non-peptide Endothelin Receptor B selective antagonist with IC50 value of 110nM.

Ro 46-2005 is an antagonist of endothelin receptor.

BQ-788 钠盐是一种有效且选择性的 ETB 受体拮抗剂，抑制 ET-1 与人 Girrardi 心脏细胞中 ETB 受体结合的 IC50 为 1.2 nM。

Aprocitentan (ACT-132577) 是 Macitentan 的主要活性代谢物。Aprocitentan 是一种双重 ETA/ETB 拮抗剂，IC50 值分别为 3.4 nM 和 987 nM，pA2 值分别为 6.7 和 5.5。

Ambrisentan is an oral, once-daily endothelin receptor antagonist that is selective for the endothelin type A receptor (IC50s = 0.251, 0.316, 0.398, 251, and 630 nM for rat preparations of heart, bladder, kidney, lung, and cerebral cortex, respectively).

Sitaxsentan sodium has selectory antagonism of endothelin A (ETA) receptor with the IC50 and Ki value of 1.4 nM and 0.43 nM respectively.

Macitentan is an antagonist of endothelin receptor A (ETA) with IC50 of 0.5 nM. It is developed for treatment of pulmonary arterial hypertension (PAH).

Bosentan hydrate竞争性双重拮抗内皮素-1（ET）对ETA和ETB受体，在人体平滑肌细胞中Ki值分别为4.7 nM和95 nM。

Sulfisoxazole is an antagonist of endothelin receptor that can be used as a sulfonamide antibacterial agent.

Sodium ferulate is the sodium salt of ferulic acid which is used for the treatment of cardiovascular disease.

Atrasentan HCl is an endothelin receptor antagonist (IC50=0.0551 nM, ETA) being developed for the treatment of prostate cancer.

Atrasentan is an endothelin receptor antagonist (IC50=0.0551 nM, ETA) being developed for the treatment of prostate cancer.

ETA antagonist 1 is a ETA selective antagonist with an IC50 of 0.08 μM.